Malaysia's Pharmaniaga signs Covid vaccine agreement with China's Sinovac
[KUALA LUMPUR] Malaysia Pharmaniaga has signed an agreement with China's Sinovac to purchase ready-to-fill Covid-19 vaccines and later to manufacture the vaccine domestically, it said on Tuesday.
Pharmaniaga said in a filing to the bourse that the company will carry out a fill-and-finish process of the vaccine in Malaysia, and will subsequently enter into local manufacturing, under license from Sinovac for its technology and know-how.
"This will also help Pharmaniaga in long-term partnerships, including technology transfer to grow the sector in Malaysia," the company said.
Malaysia has been in talks to secure a total of 23.9 million doses of Covid-19 vaccines from Sinovac and another Chinese manufacturer CanSino Biologics, and from Russia's Gamaleya Institute, the maker of the Sputnik V vaccine.
The South-east Asian nation has also procured coronavirus vaccines from US and German drugmakers Pfizer and BioNTech, as well as British-Swedish biopharmaceutical firm AstraZeneca.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Abandoned ‘Titanic’, failing ‘ancient towns’: Why China’s tourism boom leaves white elephants behind
BlackRock said to be in exclusive due diligence for Capri by Fraser China Square
‘Very low chance’ that US-Iran deal reverts energy flows to South-east Asia through Hormuz: Bloomberg Economics
Tiger Beer lines up new products as Singapore operations’ role shifts from brewing to innovation